Is Cav1.3 a feasible therapeutic target for a rare neurodevelopmental disorder?
1Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.
Expert Opinion on Therapeutic Targets
|December 13, 2024
Abstract
No abstract available in PubMed .
Keywords:
CACNA1DCa2+ channel blockersCav1.3 Ca2+ channelsde novo missense mutationsdihydropyridinesneurodevelopmental diseaseMore Related Videos
07:27Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery
Published on: June 30, 2021
2.0K
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.5K
